CURRENT
ISSUE
1574
June 17, 2019
Mild to moderate psoriasis can be treated with topical
drugs or with phototherapy. Patients with moderate to
severe disease generally require systemic therapy.... Continue reading
More from Issue 1574
Previous Issue: 1573 June 3, 2019
- Risankizumab (Skyrizi) for Psoriasis
- Romosozumab (Evenity) for Postmenopausal Osteoporosis
- Prucalopride (Motegrity) for Chronic Idiopathic Constipation
- Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
Coming Soon
Tafenoquine (Arakoda and Krintafel) for Malaria
Colon Cancer Screening
Estradiol/Progesterone (Bijuva) for Menopause
Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
Drugs for Tobacco Dependence
Subscribe
Tweets
FROM
ISSUE
1573
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier. ... Continue reading
